111 related articles for article (PubMed ID: 32639940)
21. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.
Usman MS; Siddiqi TJ; Khan MS; Ahmed A; Ali SS; Michos ED; Hall ME; Krasuski RA; Greene SJ; Butler J; Alkhouli M
Am J Cardiol; 2020 Sep; 130():159-161. PubMed ID: 32624189
[No Abstract] [Full Text] [Related]
22. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
Buckley LF; Cheng JWM; Desai A
J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766
[TBL] [Abstract][Full Text] [Related]
23. Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).
Mahajan K; Gaur N
Diabetes Metab Syndr; 2020; 14(5):723-724. PubMed ID: 32473902
[No Abstract] [Full Text] [Related]
24. Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs.
Ruilope LM; Tamargo J; Ruiz-Hurtado G
Eur Heart J; 2020 Jun; 41(22):2067-2069. PubMed ID: 32498078
[No Abstract] [Full Text] [Related]
25. Inquiring Into Benefits of Independent Activation of Nonclassical Renin-angiotensin System in the Clinical Prognosis and Reduction of COVID-19 Mortality.
Álvarez-Aragón LM; Cuesta-Muñoz AL; Álvarez-López I
Clin Infect Dis; 2020 Jul; 71(15):894-895. PubMed ID: 32266375
[No Abstract] [Full Text] [Related]
26. [2019 Novel coronavirus, renin-angiotension system imbalance and coronavirus disease 2019].
Fang Y; Guo Z; Chai Y; Zhang H; Wang Z
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 May; 32(5):613-617. PubMed ID: 32576357
[TBL] [Abstract][Full Text] [Related]
27. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
Zhou F; Liu YM; Xie J; Li H; Lei F; Yang H; Qin JJ; Cai J; Zhang XJ; Wu B; Xia M; Xiang D; Yang C; Ma X; Xu Q; Lu Z; Lu H; Xia X; Wang D; Liao X; Peng G; Yang J; Huang X; Zhang BH; Yuan Y; Wei X; Liu PP; Wang Y; Zhang P; She ZG; Xia J; Li H
Hypertension; 2020 Aug; 76(2):e15-e17. PubMed ID: 32493070
[No Abstract] [Full Text] [Related]
28. RAAS Inhibitors and Risk of Covid-19.
Sriram K; Loomba R; Insel PA
N Engl J Med; 2020 Nov; 383(20):1991-1992. PubMed ID: 33108103
[No Abstract] [Full Text] [Related]
29. RAAS Inhibitors and Risk of Covid-19.
Angeli F; Verdecchia P; Reboldi G
N Engl J Med; 2020 Nov; 383(20):1990-1991. PubMed ID: 33108102
[No Abstract] [Full Text] [Related]
30. Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19: Announcing a Large Multicentre Case-Control Study in Italy.
Di Castelnuovo A; De Caterina R; de Gaetano G; Iacoviello L
Hypertension; 2020 Aug; 76(2):312-313. PubMed ID: 32383624
[No Abstract] [Full Text] [Related]
31. Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19.
Williams B; Zhang Y
Lancet; 2020 May; 395(10238):1671-1673. PubMed ID: 32416786
[No Abstract] [Full Text] [Related]
32. Covid-19: the renin-angiotensin system imbalance hypothesis.
Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
[TBL] [Abstract][Full Text] [Related]
33. Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).
Singh AK; Gupta R; Misra A
Diabetes Metab Syndr; 2020; 14(5):729. PubMed ID: 32473904
[No Abstract] [Full Text] [Related]
34. Don't judge too RAShly: the multifaceted role of the renin-angiotensin system and its therapeutic potential in COVID-19.
Walther T; Kuebler WM
Am J Physiol Lung Cell Mol Physiol; 2020 May; 318(5):L1023-L1024. PubMed ID: 32364441
[No Abstract] [Full Text] [Related]
35. [Hypertension, RAAS blockade and risk in COVID-19 patients].
Spaak J; Kahan T
Lakartidningen; 2020 Jun; 117():. PubMed ID: 32594472
[TBL] [Abstract][Full Text] [Related]
36. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.
Kreutz R; Algharably EAE; Azizi M; Dobrowolski P; Guzik T; Januszewicz A; Persu A; Prejbisz A; Riemer TG; Wang JG; Burnier M
Cardiovasc Res; 2020 Aug; 116(10):1688-1699. PubMed ID: 32293003
[TBL] [Abstract][Full Text] [Related]
37. Sarcopenia and COVID-19: A Manifold Insight on Hypertension and the Renin Angiotensin System.
Ekiz T; Kara M; Özcan F; Ricci V; Özçakar L
Am J Phys Med Rehabil; 2020 Oct; 99(10):880-882. PubMed ID: 32657817
[No Abstract] [Full Text] [Related]
38. COVID-19 and Kidney.
Karnik ND; Trivedi M
J Assoc Physicians India; 2020 Oct; 68(10):11-12. PubMed ID: 32978918
[No Abstract] [Full Text] [Related]
39. Reply to Letter to the Editor: "Don't judge too RAShly: the multifaceted role of the renin-angiotensin system and its therapeutic potential in COVID-19".
Abassi ZA; Skorecki K; Heyman SN; Kinaneh S; Armaly Z
Am J Physiol Lung Cell Mol Physiol; 2020 May; 318(5):L1029-L1030. PubMed ID: 32364440
[No Abstract] [Full Text] [Related]
40. 5 classes of antihypertensive drugs were not linked to positive COVID-19 test results or severe COVID-19.
Fekete T
Ann Intern Med; 2020 Sep; 173(6):JC35. PubMed ID: 32926815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
